srch

March 18 (Reuters) - GlaxoSmithKline PLC: * BOSTON PHARMACEUTICALS ENTERS INTO UNIQUE MULTI-YEAR OUT-LICENSE AND OPTION AGREEMENT WITH GSK ...

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for …

Transforming the right molecules into the best medicines™. Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines ...

Boston Bags Assets From GSK and Novartis ... The US firm is getting its hands on eight programs from two of the world's leading drug makers, ...

Mar 18, 2021 · GSK will then be eligible to receive milestones and royalty payments. About Boston Pharmaceuticals. Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important unmet medical needs.

Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston ...

Under the deal, Boston Pharma will develop pre-phase 2 programs from GSK, starting with a monoclonal antibody targeting IL1RAP, a protein that ...

Boston Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a three-year out-license and option agreement to advance multiple ...

19.03.2021 · Boston Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a three-year out-license and option agreement to advance multiple pre-phase two programmes. The first two programmes are for oncology and central …

Mar 19, 2021 · Boston Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a three-year out-license and option agreement to advance multiple pre-phase two programmes. The first two programmes are for oncology and central nervous system (CNS) disorders. The latest deal builds on a previous agreement signed in 2018, where Boston Pharmaceuticals acquired ...

Mar 18, 2021 · Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceuticals ...

Initially, GSK will out-license and option two programs to Boston Pharmaceuticals: GSK3903371 - a monoclonal antibody targeting the Interleukin- ...

18.03.2021 · Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceuticals ...

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license ...

The homepage of the GSK USA website. Press releases. 20 December 2021 ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention ; 15 December 2021 GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and …

18.03.2021 · Though GSK has previously licensed five programs to Boston Pharma, it doesn’t out-license assets often, said John Lepore, M.D., senior vice president of research at GSK.

Provided GSK exercises the repurchase option, Boston Pharmaceuticals will be given a one-time payment, apart from being eligible for approval and sales royalties. If GSK does not reacquire any programme, Boston Pharmaceuticals will continue to develop and commercialise the programme, which will then make GSK eligible to for royalty payments.

UK pharma major GlaxoSmithKline (LSE: GSK) will out-license and option programs to Boston Pharmaceuticals (NYSE: BSX) under a ...

Mar 18, 2021 · Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs - The first two programs selected under the ...

18.03.2021 · Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs - The first two programs selected under the ...

Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK).

Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs 9/1/2020 We attribute our success in our pipeline to the exceptional people working at Boston Pharmaceuticals.

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK). With this agreement, Boston Pharmaceuticals will become a preferred partner to GSK for exclusive pre-phase 2 programmes, which develops on the ...

18.03.2021 · GlaxoSmithKline (NYSE:GSK) and Boston Pharmaceuticals announced a three-year out-license and option agreement for two of GSK’s pre-phase 2 candidates.; Under the agreement, GSK will out-license ...

18.03.2021 · Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs. - The first two programs selected under the agreement are for oncology and CNS disorders -. CAMBRIDGE, Mass. – Mar. 18, 2021 - Boston Pharmaceuticals [a Gurnet Point Capital portfolio company ...